Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 27: 108-112, 1981;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faraj, B. A.
Right arrow Articles by Tarcan, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faraj, B. A.
Right arrow Articles by Tarcan, Y.

Clinical Chemistry, Vol 27, 108-112, Copyright © 1981 by American Association for Clinical Chemistry

Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine

BA Faraj, DH Lawson, DW Nixon, DR Murray, VM Camp, FM Ali, M Black, W Stacciarini and Y Tarcan

This enzyme-radioimmunoassay for the measurement of L-dopa, dopamine, and 3-O-methyldopamine is based on the incubation of urine in the presence of catechol-O-methyltransferase, aromatic-L-amino-acid decarboxylase, and S-adenosylmethionine. The O-methylated dopamine metabolite formed, 3-O-methyldopamine, was characterized by radioimmunoassay. To evaluate the role of L-dopa metabolism in melanoma, we used the enzyme-radioimmunoassay to assess concentrations of L-dopa, dopamine, and 3-O-methyldopamine in urine from 10 healthy subjects, 10 hospitalized patients without melanoma and 28 patients with different degrees of melanoma. The effect of surgery for melanoma on urinary output of these catechols of melanoma patients was also evaluated. No significant difference in urinary L-dopa, dopamine, and 3- O-methyldopamine excretion rates was seen between normal subjects (L- dopa 1.3 +/- 0.3, dopamine 147 +/- 38, and 3-O-methyldopamine 31.4 +/- 13.6 microgram/24 h), hospitalized patients without melanoma, and amelanotic melanoma patients. However, the excretion rates for these metabolites in melanotic melanoma (L-dopa 5.6 +/- 1.2, dopamine 555 +/- 121, and 3-O-methyldopamine 178 +/- 40.3 microgram/24 h) were significantly (p < 0.005) higher than in control or amelanotic melanoma subjects. After surgery, there was a substantial decrease in urinary output of L-dopa and its metabolites by these patients.


The following articles in journals at HighWire Press have cited this article:


Home page
 JRSMHome page
I. S Mackenzie, M. J Ashby, T. Donovan, D. D Voutnis, and M. J Brown
Bilateral adrenal masses: phaeochromocytoma or melanoma?
J R Soc Med, March 1, 2006; 99(3): 153 - 155.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. Taran, Y. Frobert, C. Creminon, J. Grassi, D. Olichon, C. Mioskowski, and P. Pradelles
Competitive enzyme immunoassay with monoclonal antibody for homovanillic acid measurement in human urine samples
Clin. Chem., February 1, 1997; 43(2): 363 - 368.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American Association for Clinical Chemistry.